Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Asia Pacific Cystic Fibrosis Therapeutics Market Forecast 2020-2028

Published by Inkwood Research Product code 927062
Published Content info 104 Pages
Delivery time: 2-3 business days
Price
Back to Top
Asia Pacific Cystic Fibrosis Therapeutics Market Forecast 2020-2028
Published: March 2, 2020 Content info: 104 Pages
Description

KEY FINDINGS

The cystic fibrosis therapeutics market of Asia Pacific is estimated to record a CAGR of 9.58% during the projected period of 2020-2028.The rising research and development activities in terms of novel cystic fibrosis therapeutics are anticipated to create lucrative opportunities in the future.

MARKET INSIGHTS

In order to analyze the scope of the Asia Pacific cystic fibrosis therapeutics market further, the region is divided into Japan, Vietnam, Australia & New Zealand, India, Thailand, South Korea, Indonesia, China, and the rest of Asia Pacific that includes Malaysia, Nepal, Singapore, Bangladesh, etc. In the South Korean population, CF is extremely rare, though the disorder is most frequently seen in Caucasians. South Korea's health expenditure increased by 9.4% in 2018 as compared to 2017, according to the OECD Health Statistics of 2019. These factors are expected to influence the market at a steady rate. In countries like Indonesia, CF is rarely observed as per an article. The problem of under-diagnosis in countries can be due to poverty-related problems because of which CF fails to thrive, and therefore driving the market at a stable growth.

In Vietnam, few incidences of severe hereditary chronic lung disorders are expected in the country. Due to the low incidences of CF, the market is anticipated to grow at a lower rate. In Nepal, there is a prevalence of the metabolic disease as per the NCBI article. There is some government deliberation for the high incidence of congenital disorders, but disorders due to enzymatic deficiencies have not been considered for timely diagnosis and intervention. In Singapore, CF is an uncommon disease. In countries like Malaysia, 16 patients were confirmed to have CF from 1987 to 2003. These factors are estimated to propel the market in the rest of the Asia Pacific region.

COMPETITIVE INSIGHTS

F. Hoffmann-La Roche Ltd, Abbott Laboratories, Allergan PLC, Pfizer Inc, Agilent Technologies, Inc, etc. are some of the prominent companies in the market.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 29827

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
    • 3.2.2. INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
    • 3.2.3. RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. STRINGENT REGULATION
    • 3.3.2. LOW AWARENESS AMONG DEVELOPING ECONOMIES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. PESTEL ANALYSIS
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY ROUTE OF ADMINISTRATION

  • 5.1. INHALE
  • 5.2. ORAL

6. MARKET BY DRUG CLASS

  • 6.1. CFTR MODULATORS
  • 6.2. BRONCHODILATORS
  • 6.3. MUCOLYTIC
  • 6.4. PANCREATIC ENZYME SUPPLEMENTS

7. GEOGRAPHICAL ANALYSIS

  • 7.1. ASIA PACIFIC
    • 7.1.1. CHINA
    • 7.1.2. JAPAN
    • 7.1.3. INDIA
    • 7.1.4. AUSTRALIA & NEW ZEALAND
    • 7.1.5. SOUTH KOREA
    • 7.1.6. THAILAND
    • 7.1.7. INDONESIA
    • 7.1.8. VIETNAM
    • 7.1.9. REST OF ASIA PACIFIC

8. COMPANY PROFILES

  • 8.1. ABBOTT LABORATORIES
  • 8.2. ABBVIE INC
  • 8.3. AGILENT TECHNOLOGIES INC
  • 8.4. ALLERGAN PLC
  • 8.5. F. HOFFMANN-LA ROCHE
  • 8.6. GILEAD SCIENCES INC
  • 8.7. GLAXOSMITHKLINE PLC
  • 8.8. JOHNSON & JOHNSON
  • 8.9. MYLAN N.V
  • 8.10. NOVARTIS AG
  • 8.11. PERKINELMER
  • 8.12. PFIZER INC
  • 8.13. PHARMAXIS LTD
  • 8.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 8.15. VERTEX PHARMACEUTICALS INCORPORATED

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - VETERINARY VACCINE
  • TABLE 2: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: ASIA PACIFIC INHALE MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: ASIA PACIFIC INHALE MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: ASIA PACIFIC ORAL MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: ASIA PACIFIC ORAL MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: ASIA PACIFIC CFTR MODULATORS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: LIST OF CFTR MODULATORS GENERIC AND BRAND NAME
  • TABLE 12: ASIA PACIFIC CFTR MODULATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 13: ASIA PACIFIC BRONCHODILATORS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 14: LIST OF BRONCHODILATORS GENERIC AND BRAND NAME
  • TABLE 15: ASIA PACIFIC BRONCHODILATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: ASIA PACIFIC MUCOLYTIC MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: LIST OF MUCOLYTICS GENERIC AND BRAND NAME
  • TABLE 18: ASIA PACIFIC MUCOLYTIC MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 19: ASIA PACIFIC PANCREATIC ENZYME SUPPLEMENTS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 20: ASIA PACIFIC PANCREATIC ENZYME SUPPLEMENTS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 21: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 22: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, IN 2019
  • FIGURE 6: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY INHALE, 2020-2028 (IN $ MILLION)
  • FIGURE 7: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ORAL, 2020-2028 (IN $ MILLION)
  • FIGURE 8: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, IN 2019
  • FIGURE 9: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY CFTR MODULATORS, 2020-2028 (IN $ MILLION)
  • FIGURE 10: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY BRONCHODILATORS, 2020-2028 (IN $ MILLION)
  • FIGURE 11: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY MUCOLYTIC, 2020-2028 (IN $ MILLION)
  • FIGURE 12: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY PANCREATIC ENZYME SUPPLEMENTS, 2020-2028 (IN $ MILLION)
  • FIGURE 13: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 14: CHINA CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
  • FIGURE 15: JAPAN CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
  • FIGURE 16: INDIA CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
  • FIGURE 17: AUSTRALIA & NEW ZEALAND CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
  • FIGURE 18: SOUTH KOREA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 19: THAILAND CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 20: INDONESIA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 21: VIETNAM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 22: REST OF ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
Back to Top